Evidence map›Paper›PMID 21986317›Full record

ArticleProceedings of the Japan Academy. Series B, Physical and biological sciences2011

Adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy.

Osamu Suzuki, Takao Kanai, Toshio Nishikawa, Yoshie Yamamoto, Akira Noguchi, Kazuhiro Takimoto, Minako Koura, Yoko Noguchi, Kozue Uchio-Yamada, Shuichi Tsuji and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Development of Animal Models for Preclinical Safety Studies.Advances in experimental medicine and biology · 2025
    Review
  2. Alterations of the Sialylation Machinery in Brugada Syndrome.International journal of molecular sciences · 2022
    Article
  3. Article
  4. Article
  5. TRPV2 channel as a possible drug target for the treatment of heart failure.Laboratory investigation; a journal of technical methods and pathology · 2020
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Osamu SuzukiLaboratory of Animal Models for Human Diseases, National Institute of Biomedical Innovation, Ibaraki, Japan. osuzuki@nibio.go.jp
Takao Kanai
Toshio Nishikawa
Yoshie Yamamoto
Akira Noguchi
Kazuhiro Takimoto
Minako Koura
Yoko Noguchi
Kozue Uchio-Yamada
Shuichi Tsuji
Junichiro Matsuda
National Institute of Biomedical Innovation, Health and Nutrition · JPNational Institute of Infectious Diseases · JPTokyo Women's Medical University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sugar chain abnormalities in glycolipids and glycoproteins are associated with various diseases. Here, we report an adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes. The transgenic hearts at the end-stage, at around 7 months old, were enlarged, with enlarged cavities and thin, low-tensile walls, typical of dilated cardiomyopathy. Although no apparent change was found in heart gangliosides, glycosylation of heart proteins was altered. Interestingly, sugar moieties not directly related to the ST3Gal-II catalytic reaction were also changed. Significant increases in calreticulin and calnexin were observed in hearts of the transgenic mice. These results suggest that expression of ST3Gal-II transgenes induces abnormal protein glycosylation, which disorganizes the endoplasmic/sarcoplasmic reticulum quality control system and elevates the calreticulin/calnexin level, resulting in suppression of cardiac function. The transgenic mice showed 100% incidence of adult onset cardiac dilatation, suggesting great potential as a new model for dilated cardiomyopathy.

Indexed as

AgingAnimalsbeta-Galactoside alpha-2,3-SialyltransferaseCalnexinCalreticulinCardiomyopathy, DilatedDisease Models, AnimalFrozen SectionsGangliosidesHomozygoteLectinsMiceMice, Inbred C57BLMice, TransgenicMyocardiumOrgan Specificitybeta-Galactoside alpha-2,3-SialyltransferaseCalnexinCalreticulinGangliosidesLectinsSialyltransferases

Identifiers

PMID21986317
PMCPMC3313694
OpenAlexW2057001407

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.